LITEAugust 15, 2026 at 9:54 AM UTCSemiconductors & Semiconductor Equipment

Lumentum's Q4 blowout and strong guide vindicate AI ramp, but premium valuation keeps discipline essential.

Read source article

What happened

Lumentum's fiscal fourth quarter results exceeded the high end of guidance, with revenue surging 109% year over year to $1.01 billion and non-GAAP operating margin expanding to 36.6%. The company guided for another 24% sequential revenue growth in the first quarter of fiscal 2027, with EPS expected to rise about 30% as operating margin approaches 40%. Management attributed the strength to accelerating AI data center demand for 1.6T transceivers, optical circuit switches, and ultra-high-power lasers, which remain early-stage growth drivers. The results directly address a key checkpoint from the previous analysis, which had flagged the risk that supply constraints and ASP pressure could temper margin expansion. While the quarter is a clear positive, the article's bullish tone must be weighed against the company's own filings, which caution that most customers lack long-term purchase commitments and backlog may not be reliable.

Implication

The blowout quarter and strong guidance reduce the probability of a near-term demand air-pocket and support the bull case that Lumentum is a critical supplier in the AI data center buildout. However, the stock's premium valuation (168x trailing EPS and 759x EV/EBITDA as of May) means that much of the good news is already reflected, leaving little margin for error if growth decelerates. The persistent lack of long-term customer commitments and the unusual insider selling pattern noted in prior filings remain yellow flags that the current demand may be more cyclical than secular. Investors who are long should hold with a trailing stop or reduce into strength if the stock approaches the bull-case implied value of $1,200, while those on the sidelines should wait for a pullback toward the base-case $900 level or confirmation of durable contracts. Overall, the risk-reward has improved from a pure wait, but the stock is not yet a compelling buy at current levels without evidence of pricing stability and contracted revenue visibility.

Thesis delta

The previous WAIT rating was predicated on uncertainty about FQ4 execution and margin durability. The reported results and forward guide materially de-risk the near-term demand picture, shifting the balance of probabilities toward the bull case. However, the lack of contractual commitments and elevated valuation prevent an outright upgrade to BUY, favoring a more constructive but still selective stance.

Confidence

medium-high